HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29048-29059

  Liu, Peng ^a   Zhang, Hualin ^a   Liang, Xiaohong ^a   Ma, Hongxin ^a   Luan, Fang ^b   Wang, Bo ^a   Bai, Fuxiang ^a   Gao, Lifen ^a   Ma, Chunhong ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

HCC; Hippo pathway; MiRNA 338 3p; PreS2; TAZ

Indexed keywords

CELL PROTEIN; HIPPO PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 338 3P; PRES2 PROTEIN; REGULATOR PROTEIN; TAZ PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; HEPATITIS B SURFACE ANTIGEN; MIRN338 MICRORNA, HUMAN; PRESURFACE PROTEIN 2, HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR; SIGNAL PEPTIDE; WWTR1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CARCINOMA CELL LINE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; RNA PROCESSING; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR VOLUME; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATITIS B SURFACE ANTIGENS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MICRORNAS; PROTEIN PRECURSORS; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UP-REGULATION;

EID: 84945161773     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4804     Document Type: Article

References (58)

1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014; 384:2053-2063.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009; 373:582-592.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-2576.
4. Parkin DM. The global health burden of infectionassociated cancers in the year 2002. Int J Cancer. 2006; 118:3030-3044.
5. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature. 1980; 286:533-535.
6. Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D, et al. Hepatitis B virusrelated insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene. 2003; 22:3911-3916.
7. Zhong S, Chan JY, Yeo W, Tam JS, Johnson PJ. Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues. J Viral Hepat. 1999; 6:195-202.
8. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J. 2002; 21:525-535.
9. Hildt E, Saher G, Bruss V, Hofschneider PH. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology. 1996; 225:235-239.
10. Hildt E, Urban S, Hofschneider PH. Characterization of essential domains for the functionality of the MHBst transcriptional activator and identification of a minimal MHBst activator. Oncogene. 1995; 11:2055-2066.
11. Zhang X, Gao L, Liang X, Guo M, Wang R, Pan Y, Liu P, et al. HBV preS2 transactivates FOXP3 expression in malignant hepatocytes. Liver Int. 2014;.
12. Luan F, Liu H, Gao L, Liu J, Sun Z, Ju Y, Hou N, et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut. 2009; 58:1528-1537.
13. Pantalacci S, Tapon N, Leopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol. 2003; 5:921-927.
14. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003; 5:914-920.
15. Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003; 114:457-467.
16. Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003; 114:445-456.
17. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130:1120-1133.
18. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21:2747-2761.
19. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, et al. TAZ promotes cell proliferation and epithelialmesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008; 28:2426-2436.
20. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009; 16:425-438.
21. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007; 17:2054-2060.
22. Sudol M. Newcomers to the WW Domain-Mediated Network of the Hippo Tumor Suppressor Pathway. Genes Cancer. 2010; 1:1115-1118.
23. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011; 30:2181-2186.
24. Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget. 2014; 5:9619-9625.
25. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008; 68:2592-2598.
26. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem. 2009; 284:14347-14358.
27. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147:759-772.
28. Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, Shan C, et al. Hepatitis B virus X protein modulates oncogene Yesassociated protein by CREB to promote growth of hepatoma cells. Hepatology. 2012; 56:2051-2059.
29. Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow P, Chung AY, et al. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol. 2010; 53:57-66.
30. Wu G, Yu F, Xiao Z, Xu K, Xu J, Tang W, Wang J, et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer. 2011; 105:146-153.
31. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One. 2011; 6:e19518.
32. Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, Wu Z. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal. 2013; 25:439-446.
33. Sheng Y, Li J, Zou C, Wang S, Cao Y, Zhang J, Huang A, et al. Downregulation of miR-101-3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a. Arch Virol. 2014; 159:2397-2410.
34. Fu X, Tan D, Hou Z, Hu Z, Liu G. miR-338-3p Is DownRegulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 3'-UTR Region of CyclinD1. Int J Mol Sci. 2012; 13:8514-8539.
35. Wang Y, Gao Y, Shi W, Zhai D, Rao Q, Jia X, Liu J, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark. 2015; 15:177-186.
36. Zuo QF, Zhang R, Li BS, Zhao YL, Zhuang Y, Yu T, Gong L, et al. MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional coactivator with PDZ-binding motif, TAZ. Cell Death Dis. 2015; 6:e1623.
37. Yuan J, Xiao G, Peng G, Liu D, Wang Z, Liao Y, Liu Q, et al. MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differentiation by targeting TAZ. Biochem Biophys Res Commun. 2015; 457:171-176.
38. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, Chen LZ, Bi J, et al. miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol. 2011; 225:463-472.
39. Xiao H, Jiang N, Zhou B, Liu Q, Du C. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 2015; 106:151-159.
40. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015; 34:681-690.
41. Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 2014; 33:468-481.
42. Geier A, Gartung C, Dietrich CG. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. N Engl J Med. 2002; 347:1721-1722. author reply 1721-1722.
43. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002; 36:1206-1213.
44. Han SX, Bai E, Jin GH, He CC, Guo XJ, et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014; 2014:261365
45. Schluter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH. Integrated hepatitis B virus X and 3'truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene. 1994; 9:3335-3344.
46. Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, et al. MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1alpha. PLoS One. 2014; 9:e115565.
47. Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD, Gregory RI. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 2014; 156:893-906.
48. Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ, Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA. 2008; 14:35-42.
49. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435:834-838.
50. Li S, Ran Y, Zhang D, Chen J, Li S, Zhu D. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem J. 2013; 452:281-291.
51. Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L, Sun Y, et al. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene. 2012; 31:4067-4075.
52. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010; 120:1298-1309.
53. Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, O'Malley YQ, et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 2012; 11:4352-4365.
54. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, et al. MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun. 2013; 4:1877.
55. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010; 394:623-627.
56. Zhang ZW, Men T, Feng RC, Li YC, Zhou D, Teng CB. miR-375 inhibits proliferation of mouse pancreatic progenitor cells by targeting YAP1. Cell Physiol Biochem. 2013; 32:1808-1817.
57. Bracken CP, Li X, Wright JA, Lawrence DM, Pillman KA, Salmanidis M, Anderson MA, et al. Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion. EMBO J. 2014; 33:2040-2056.
58. Liu H, Luan F, Ju Y, Shen H, Gao L, Wang X, Liu S, et al. In vitro transfection of the hepatitis B virus PreS2 gene into the human hepatocarcinoma cell line HepG2 induces upregulation of human telomerase reverse transcriptase. Biochem Biophys Res Commun. 2007; 355:379-384.